H.C. Wainwright analyst Oren Livnat assumed coverage of Tarsus Pharmaceuticals (TARS) with a Buy rating and $72 price target The firm likes the company’s Xdemvy impetus in Demodex blepharitis. Xdemvy represents the first and only FDA approved therapy to treat Demodex blepharitis, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- Elanco sells royalty, milestone rights for Xdemvy to Blackstone for $295M
- Tarsus Pharmaceuticals’ Earnings Call Highlights Robust Growth
- Tarsus Pharmaceuticals: Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating
- Tarsus Pharmaceuticals price target raised to $84 from $78 at Guggenheim
- Tarsus Pharmaceuticals Reports Strong Q1 2025 Growth
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue